Cargando…

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis

The prognostic heterogeneity in patients with BRAF V600E metastatic colorectal cancer (mCRC) remains poorly defined. Real-world data of 93 BRAF V600E mCRC patients from Sun Yat-sen University Cancer Center were evaluated using the prognostic factors affecting overall survival (OS). Treatment of meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Liu-Fang, Ji, Xiao-Meng, Ren, Chao, Wang, Zhi-Qiang, Lin, Chun-Ping, Chen, Dong-Liang, Cai, Yan-Qing, Jin, Ying, Qiu, Miao-Zhen, Du, Zi-Ming, Xi, Shao-Yan, Zhang, Dong-Sheng, Wang, Feng, Wang, Feng-Hua, Xu, Rui-Hua, Li, Yu-Hong, Wang, De-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468777/ https://www.ncbi.nlm.nih.gov/pubmed/34572480 http://dx.doi.org/10.3390/biom11091268

Ejemplares similares

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
por: Yuan, Zi-Xu, et al.
Publicado: (2013)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
por: Guan, Wen-Long, et al.
Publicado: (2020)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
por: Kanat, Ozkan, et al.
Publicado: (2020)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
por: Guerrero, Rodrigo Motta, et al.
Publicado: (2022)

Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
por: Wang, Zhan, et al.
Publicado: (2019)

The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report
por: Wang, Zhan, et al.
Publicado: (2020)

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas
por: Angerilli, V., et al.
Publicado: (2021)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2016)

A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
por: Bai, Long, et al.
Publicado: (2015)

CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2019)

Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer
por: Yang, Yingchi, et al.
Publicado: (2018)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
por: Serra, Francesco, et al.
Publicado: (2021)

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response
por: Li, Zhe-Zhen, et al.
Publicado: (2016)

BRAF(V600E) Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
por: Gourdin, Guillaume, et al.
Publicado: (2023)

Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms
por: Wang, Zi-Xian, et al.
Publicado: (2016)

BRAF(V600E) mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs
por: Zhi, Jie, et al.
Publicado: (2021)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Clinicopathological Significance of BRAF(V600E) Mutation in Colorectal Cancer: An Updated Meta-Analysis
por: Wang, Jianhua, et al.
Publicado: (2019)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Mps1 is associated with the BRAF(V600E) mutation and predicts poor outcome in patients with colorectal cancer
por: Zhang, Yanyan, et al.
Publicado: (2019)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma
por: Li, Zhenxiang, et al.
Publicado: (2015)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis
por: Hong, Ling, et al.
Publicado: (2022)

Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
por: Xia, Rong-Hui, et al.
Publicado: (2021)

High BRAF(V600E) mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules
por: Li, Xing-Jia, et al.
Publicado: (2019)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbkhrfpe8clp9sbv3hod8ttsng